𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyperfractionated accelerated radiochemotherapy (HFA-RCT) with mitomycin C for advanced head and neck cancer

✍ Scribed by J. Widder; W. Dobrowsky; R. Schmid; B. Pokrajac; E. Selzer; R. Pötter

Book ID
118496290
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
86 KB
Volume
73
Category
Article
ISSN
0167-8140

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved results with accelerated hyperf
Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer
✍ Felix Leborgne; Eduardo Zubizarreta; Jack Fowler; Bettys Ortega; Julieta Mezzera 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 309 KB 👁 2 views

A retrospective study on local tumor control, survival, and complications of conventional irradiation vs. accelerated hyperfractionated irradiation in patients with selected head and neck cancer sites was undertaken. A total of 1,007 consecutive patients treated with radiation alone for cure from 19

Acceleration of hyperfractionated chemor
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer
✍ Aaron M. Allen; Mohamed Elshaikh; Francis P. Worden; Carol R. Bradford; Theodoro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). ## Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regime

Concomitant radiochemotherapy in primary
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C
✍ Hans Christiansen; Robert M. Hermann; Andrea Hille; Elisabeth Weiss; Mirko Nitsc 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 534 KB

## Abstract ## Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5‐fluorouracil (5‐FU) and mitomycin‐C infusion in inoperable head and neck cancer. ## Methods. Seventy‐six patients (86% men, 14% women), mean age 57 years, with primary